Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ljiljana B Rakicevic

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Journal of Thrombosis and Thrombolysis|June 4, 2011
Extreme sensitivity to acenocoumarol therapy in patient with both VKORC.-1639 A/A and CYP2C9*1/*3 genotypesMirjana K Kovac, Ljiljana B Rakicevic, Dragica P Radojkovic
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|June 29, 2010
The c.-1639G>A polymorphism of the VKORC1 gene in Serbian population: retrospective study of the variability in response to oral anticoagulant therapyMirjana K Kovac, Aleksandar R Maslac, Ljiljana B Rakicevic, et al.
Journal of Thrombosis and Thrombolysis|July 6, 2012
Pharmacogenetic tests could be helpful in predicting of VKA maintenance dose in elderly patients at treatment initiationMirjana K Kovac, Ljiljana B Rakicevic, Jelena S Kusic-Tisma, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|June 29, 2013
Rationalized DNA sequencing-based protocol for genotyping patients receiving coumarin therapyLjiljana B Rakicevic, Jelena S Kusic-Tisma, Mirjana K Kovac, et al.
Pharmacogenomics|October 22, 2016
Economic analysis of pharmacogenomic-guided clopidogrel treatment in Serbian patients with myocardial infarction undergoing primary percutaneous coronary interventionChristina Mitropoulou, Vasilios Fragoulakis, Ljiljana B Rakicevic, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|September 14, 2013
Risk factors for thrombosis in Serbian childrenOlivera M Serbic-Nonkovic, Milos B Kuzmanovic, Ljiljana B Rakicevic, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Journal of Thrombosis and Thrombolysis|June 4, 2011
Extreme sensitivity to acenocoumarol therapy in patient with both VKORC.-1639 A/A and CYP2C9*1/*3 genotypesMirjana K Kovac, Ljiljana B Rakicevic, Dragica P Radojkovic
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|June 29, 2010
The c.-1639G>A polymorphism of the VKORC1 gene in Serbian population: retrospective study of the variability in response to oral anticoagulant therapyMirjana K Kovac, Aleksandar R Maslac, Ljiljana B Rakicevic, et al.
Journal of Thrombosis and Thrombolysis|July 6, 2012
Pharmacogenetic tests could be helpful in predicting of VKA maintenance dose in elderly patients at treatment initiationMirjana K Kovac, Ljiljana B Rakicevic, Jelena S Kusic-Tisma, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|June 29, 2013
Rationalized DNA sequencing-based protocol for genotyping patients receiving coumarin therapyLjiljana B Rakicevic, Jelena S Kusic-Tisma, Mirjana K Kovac, et al.
Pharmacogenomics|October 22, 2016
Economic analysis of pharmacogenomic-guided clopidogrel treatment in Serbian patients with myocardial infarction undergoing primary percutaneous coronary interventionChristina Mitropoulou, Vasilios Fragoulakis, Ljiljana B Rakicevic, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|September 14, 2013
Risk factors for thrombosis in Serbian childrenOlivera M Serbic-Nonkovic, Milos B Kuzmanovic, Ljiljana B Rakicevic, et al.
Pageof 1